NCT04345796View on ClinicalTrials.gov

Pharmacological Reduction of Right Ventricular Enlargement

PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
Tricuspid RegurgitationRight Ventricular Dilatation
Interventions
DRUG

Carvedilol+Empagliflozin

Group A

DRUG

Carvedilol

Group B

DRUG

Empagliflozin

Group C

DRUG

Placebo

Group D

Trial Locations (3)

138-736

Asan Medical Center, Seoul

Unknown

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Chong Kun Dang Pharmaceutical Corporation

UNKNOWN

lead

Asan Medical Center

OTHER